TD Asset Management’s Ginkgo Bioworks DNA Stock Holding History

TD Asset Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,046	Closed	-$80K	–	1242
2026 Q1	$80K	Hold	13,046	–	–	﹤0.01%	1227
2025 Q4	$108K	Hold	13,046	–	–	﹤0.01%	1229
2025 Q3	$190K	Hold	13,046	–	–	﹤0.01%	1225
2025 Q2	$147K	Hold	13,046	–	–	﹤0.01%	1182
2025 Q1	$74.4K	Hold	13,046	–	–	﹤0.01%	1212
2024 Q4	$128K	Hold	13,046	–	–	﹤0.01%	1237
2024 Q3	$106K	Hold	13,046	–	–	﹤0.01%	1376
2024 Q2	$174K	Hold	13,046	–	–	﹤0.01%	1345
2024 Q1	$605K	Hold	13,046	–	–	﹤0.01%	1265
2023 Q4	$882K	Hold	13,046	–	–	﹤0.01%	1198
2023 Q3	$945K	Buy	13,046 +6,523	+100%	+$522K	﹤0.01%	1156
2023 Q2	$485K	Hold	6,523	–	–	﹤0.01%	1271
2023 Q1	$347K	Hold	6,523	–	–	﹤0.01%	1319
2022 Q4	$441K	Hold	6,523	–	–	﹤0.01%	1305
2022 Q3	$817K	Hold	6,523	–	–	﹤0.01%	1217
2022 Q2	$621K	Sell	6,523 -7,315	-53%	-$892K	﹤0.01%	1256
2022 Q1	$2.23M	Buy	13,838 +6,498	+89%	+$1.26M	﹤0.01%	1057
2021 Q4	$2.44M	Buy	7,340 +5,097	+227%	+$2.42M	﹤0.01%	1085
2021 Q3	$1.04M	Buy	+2,243	New	+$1.09M	﹤0.01%	1243

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1.16B AUM 53.61% 1-Year Est. Return

TD Asset Management's DNA Position: Q2 2026 in Review

TD Asset Management sold out of Ginkgo Bioworks (DNA) in Q2 2026, closing a stake of 13,046 shares — an estimated $80K sold.

TD Asset Management first reported a position in DNA in Q3 2021 and held it in 19 quarters. The position peaked at $2.44M in Q4 2021. 127 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

TD Asset Management reported no remaining Ginkgo Bioworks position as of Q2 2026 after selling out during the quarter.
TD Asset Management sold 13,046 Ginkgo Bioworks shares in Q2 2026, an estimated $80K.
TD Asset Management first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 19 quarters.
TD Asset Management's Ginkgo Bioworks position peaked at $2.44M in Q4 2021.
127 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.